China Pharma Holdings, Inc. — Q3 2012 Form 10-Q
Business and period: The company manufactures and sells generic and branded pharmaceuticals in China through its subsidiary Helpson. This unaudited quarterly report covers the three and nine months ended September 30, 2012; comparisons are to the corresponding 2011 periods. All operating activity is in the PRC, and results are reported in U.S. dollars.
Financial performance
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | $12.18 million | $20.99 million | $42.86 million | $58.71 million |
| Gross profit / margin | $3.24 million / 26.6% | $7.51 million / 35.8% | $12.69 million / 29.6% | $21.67 million / 36.9% |
| Operating income | $1.62 million | $5.96 million | $7.24 million | $17.06 million |
| Net income | $1.30 million | $4.97 million | $5.86 million | $15.15 million |
| Diluted EPS | $0.03 | $0.11 | $0.13 | $0.35 |
- Q3 revenue fell 42% year over year and nine-month revenue fell 27%. Management attributed the declines to healthcare-reform-related pricing changes, uneven market reactions, and reduced credit sales.
- Nine-month gross margin declined 7.3 percentage points. Management cited product price pressure and rising pharmaceutical material costs. Q3 declines were particularly pronounced in CNS/cardiovascular, digestive, and other product margins.
- Nine-month operating income decreased 58% and net income decreased 61%. Results also compare against a $934,000 derivative gain recorded in 2011; no such gain was recorded in 2012.
Financial position, cash flow and liquidity
- At September 30, 2012, cash and cash equivalents were $5.06 million; banker’s acceptances were $0.37 million. Current assets were $118.70 million and current liabilities $16.54 million.
- Trade receivables, net, were $69.82 million, approximately unchanged from year-end 2011. The filing reports $64.6 million past due and says the share of receivables aged 361–720 days rose to 34.7% from 20.4% at December 31, 2011. The doubtful-account allowance increased to $4.27 million from $3.54 million.
- Inventory rose to $37.81 million from $30.38 million, mainly from raw-material purchases and a temporary increase in finished goods ahead of facility upgrades. Advances for intangible assets were $37.69 million.
- For the first nine months, operating cash flow was $2.97 million, down from $5.41 million. Investing cash outflow was $2.38 million; financing cash inflow was $0.39 million, consisting of a related-party advance. Cash increased by $1.01 million.
- Short-term notes payable were $3.96 million at quarter-end, bearing 7.54% interest and secured by land-use rights and buildings. The loan was repaid October 18 and not renewed at maturity. A new RMB30 million revolving facility was entered into October 30 at 6.90%; approximately $4.75 million was outstanding as of November 9. No long-term borrowings are reported.
- Management states that $5.43 million of cash and banker’s acceptances was considered indefinitely reinvested in Helpson and not expected to be available for parent-company or shareholder payments. PRC currency-conversion and remittance controls may also restrict transfers.
Changes, outlook and risks
- All major product categories had lower nine-month sales. In Q3, CNS/cardiovascular revenue fell 56%, anti-infective/respiratory fell 37%, and digestive-disease revenue fell 62%; “Other” increased 8%. Management identified Ozagrel Sodium for Injection and Buflomedil Hydrochloride among the principal contributors to CNS/cardiovascular weakness.
- Management expects continued pricing pressure and an uncertain pricing environment. It said new products, including Candesartan and Rosuvastatin, could support margins after launch. Candesartan received SFDA production approval in November 2012, after quarter-end, and the company planned production in Q1 2013. Rosuvastatin had been submitted for production approval; a coronary heart disease drug was in Phase III trials, with trial completion anticipated by year-end 2012. These are forward-looking statements, not assurances.
- Two injectable production lines must meet updated Chinese GMP standards by the end of 2013. The company reported planning and construction activity; about $1.4 million of the period’s spending related to facility upgrades.
- The company had $37.69 million in advances for unapproved medical formulas. SFDA approval typically takes two to five years; no formulas received production approval during the first nine months of 2012. Contractual refund or substitution rights apply if approval is denied or a laboratory breaches its contract, but recovery is not assured.
- Additional risks include the aging receivables and rising bad-debt expense, PRC pricing and regulatory changes, RMB exchange/remittance restrictions, reliance on a supplier representing 14.6% of raw-material purchases, and the scheduled rise in the PRC income-tax rate from 15% through 2013 to 25% in 2014 and thereafter. The company reported no material off-balance-sheet arrangements or commitments beyond ordinary-course expenditures.
- Management concluded disclosure controls were effective as of September 30, 2012 and reported no material change in internal control over financial reporting during the quarter. The financial statements are unaudited and interim results are not necessarily indicative of full-year results.
Important facts for investors to verify
- Whether the sharp sales and margin declines persist, and how pricing reforms affect products and regional demand.
- Receivable aging and subsequent collections, particularly the reported $64.6 million past-due balance and growth in older receivables.
- Progress on the injectable-line GMP upgrades and the ability to meet the end-2013 deadline.
- SFDA approval, launch timing, commercial uptake, and margin contribution of Candesartan, Rosuvastatin, and pipeline products.
- Whether advances for unapproved formulas are recoverable if approvals are delayed or denied, and how much cash can be transferred from the PRC subsidiary.
- Terms, collateral and repayment status of the replacement bank facility, and the company’s liquidity needs amid inventory and investment spending.